Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin

被引：1
|
作者：
Sahin, Mustafa [1 ]
Miskioglu, Mine [2 ]
Inanir, Isil [3 ]
Akar, Hikmet [1 ]
Nese, Nalan [4 ]
Temiz, Peyker [4 ]
Aydogdu, Ismet [2 ]
机构：
[1] Celal Bayar Univ, Fac Med, Dept Internal Med, Manisa, Turkey
[2] Celal Bayar Univ, Fac Med, Dept Hematol, Manisa, Turkey
[3] Celal Bayar Univ, Fac Med, Dept Dermatol, Manisa, Turkey
[4] Celal Bayar Univ, Fac Med, Dept Patol, Manisa, Turkey
来源：
TURKISH JOURNAL OF HEMATOLOGY | 2021年 / 38卷 / 01期
关键词：
Cutaneous anaplastic large cell lymphoma; Brentuximab; Monotherapy; Breast cancer;
D O I：
10.4274/tjh.galenos.2020.2020.0512
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：85 / 87
页数：4
相关论文
共 50 条
  • [41] Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report
    Floyd, Erin G.
    Burns, Timothy F.
    Linos, Konstantinos
    LeBlanc, Robert E.
    Carter, Joi B.
    Jarvis, Lesley A.
    Lansigan, Frederick
    JOURNAL OF HEMATOLOGY, 2019, 8 (03) : 132 - 136
  • [42] Primary cutaneous anaplastic large-cell lymphoma: A case report
    Whitney, Kristen
    Altman, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB162 - AB162
  • [43] Anaplastic large-cell lymphoma
    Inghirami, Giorgio
    Pileri, Stefano A.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2011, 28 (03) : 190 - 201
  • [44] BRENTUXIMAB VEDOTIN: ITS ROLE IN THE TREATMENT OF ANAPLASTIC LARGE CELL AND HODGKIN'S LYMPHOMA
    Haddley, K.
    DRUGS OF TODAY, 2012, 48 (04) : 259 - 270
  • [45] Successful Therapy with Brentuximab Vedotin at clinic-adapted Delivery Intervals in primary cutaneous, CD30-positive, large-cell, anaplastic T-cell Lymphoma
    Bley, L. I.
    Schulze, H. J.
    Grundmann, S.
    Weishaupt, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 45 - 45
  • [46] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [47] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Eric L Sievers
    Nature Biotechnology, 2012, 30 : 631 - 637
  • [48] Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin
    Nakai, Ritsuko
    Fukuhara, Suguru
    Maeshima, Akiko Miyagi
    Kim, Sung-Won
    Ito, Yuta
    Hatta, Shunsuke
    Suzuki, Tomotaka
    Yuda, Sayako
    Makita, Shinichi
    Munakata, Wataru
    Suzuki, Tatsuya
    Maruyama, Dai
    Izutsu, Koji
    CLINICAL CASE REPORTS, 2019, 7 (12): : 2500 - 2504
  • [49] Extended use of brentuximab vedotin before autologous stem-cell transplantation would benefit refractory systemic anaplastic large-cell lymphoma
    Koh, Youngil
    CLINICAL CASE REPORTS, 2018, 6 (05): : 798 - 801
  • [50] Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma
    Foyil, Kelley V.
    Kennedy, Dana A.
    Grove, Laurie E.
    Bartlett, Nancy L.
    Cashen, Amanda F.
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 506 - 507
12345